Cat. No. 1998
Biological ActivityPotent, metabolically stable neurotensin receptor agonist peptide (IC50 = 0.15 nM for inhibition of [125I]-NT binding to neonatal mouse brain; EC50 = 1.9 nM for contraction of guinea pig ileum). Produces long-lasting hypothermic, neuroprotective and analgesic effects in mice following central administration in vivo.
(Modifications: Lys-1 - Lys-2 peptide bond replace with Ψ(CH2-NH))
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Lugrin et al (1991) Reduced peptide bond pseudopeptide analogues of neurotensin: binding and biological activities, and in vitro metabolic stability. Eur.J.Pharmacol. 205 191. PMID: 1812009.
Dubuc et al (1992) JMV 449: a pseudopeptide analogue of neurotensin-(8-13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse. Eur.J.Pharmacol. 219 327. PMID: 1425958.
Torup et al (2003) Neuroprotective effect of the neurotensin analogue JMV-449 in a mouse model of permanent middle cerebral ischaemia. Neurosci.Lett. 351 173. PMID: 14623134.
If you know of a relevant citation for this product please let us know.
Keywords: JMV 449, supplier, Potent, neurotensin, receptor, agonists, NT, Receptors, JMV449
Find multiple products by catalog number
New Products in this Area
Oxytocin analogML 221
Apelin receptor (APJ) antagonistQ94 hydrochloride
Negative allosteric modulator at PAR1 receptorFSLLRY-NH2
PAR2 peptide antagonistSB 611812
Urotensin-II (UT) antagonist; attenuates cardiac dysfunctionTC-MCH 7c
Selective melanin-concentrating hormone receptor 1 (MCH1R) antagonistCYM 9484
Potent NPY Y2 receptor antagonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.